Jane Street Group LLC Acquires 109,769 Shares of The Oncology Institute, Inc. (NASDAQ:TOI)

Jane Street Group LLC raised its stake in The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) by 613.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 127,659 shares of the company's stock after purchasing an additional 109,769 shares during the period. Jane Street Group LLC owned 0.17% of Oncology Institute worth $39,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Renaissance Technologies LLC grew its position in shares of Oncology Institute by 7.1% during the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock worth $56,000 after acquiring an additional 12,000 shares during the last quarter. Virtu Financial LLC bought a new stake in Oncology Institute in the 4th quarter valued at about $41,000. FreeGulliver LLC boosted its stake in Oncology Institute by 219.3% during the 4th quarter. FreeGulliver LLC now owns 600,747 shares of the company's stock valued at $186,000 after purchasing an additional 412,578 shares during the period. Finally, Tiff Advisory Services LLC grew its position in Oncology Institute by 13.2% in the 4th quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company's stock worth $921,000 after purchasing an additional 346,256 shares during the last quarter. Institutional investors and hedge funds own 36.86% of the company's stock.

Insider Transactions at Oncology Institute

In other news, Director Growth I. L.P. M33 sold 203,532 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $2.71, for a total value of $551,571.72. Following the transaction, the director now directly owns 1,349,048 shares of the company's stock, valued at approximately $3,655,920.08. This represents a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark L. Pacala acquired 90,562 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were purchased at an average price of $1.04 per share, with a total value of $94,184.48. Following the completion of the acquisition, the director now owns 224,971 shares of the company's stock, valued at $233,969.84. This represents a 67.38% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 122,258 shares of company stock valued at $127,148 and sold 4,726,137 shares valued at $13,379,013. 8.50% of the stock is owned by insiders.

Oncology Institute Trading Up 7.5%

Oncology Institute stock traded up $0.20 during midday trading on Wednesday, reaching $2.86. The stock had a trading volume of 1,872,068 shares, compared to its average volume of 1,004,545. The Oncology Institute, Inc. has a twelve month low of $0.13 and a twelve month high of $3.50. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The firm has a market cap of $255.21 million, a price-to-earnings ratio of -3.67 and a beta of 0.13. The firm's fifty day simple moving average is $2.56 and its two-hundred day simple moving average is $1.30.

Oncology Institute (NASDAQ:TOI - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter. The business had revenue of $104.41 million for the quarter. Oncology Institute had a negative net margin of 17.63% and a negative return on equity of 186.83%.

Wall Street Analysts Forecast Growth

Separately, BTIG Research assumed coverage on Oncology Institute in a report on Thursday, May 15th. They set a "buy" rating and a $7.00 price objective on the stock.

Oncology Institute Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.